MedClean Technologies, Inc.(fka MCLN)

[Slyder75]

Folks, I missed this yesterday...

MCLN back on Reg Sho as of July 15th. I can't believe I missed this...

http://www.otcmarkets.com/stock/MCLN/short-sales

BUYINS.NET: MIPI, MCLN, NEXMD Have Been Added To Naked Short Lists Today

Jul 16, 2010 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold lists. Molecular Insight Pharmaceuticals (NASDAQ: MIPI), MedClean Technologies (OTCBB: MCLN) and NexMed (NASDAQ: NEXMD). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapeutic and imaging radiopharmaceuticals for use in oncology. The company develops its lead radiotherapeutic oncology product candidate, Azedra, which is in pivotal Phase IIb trials for the treatment of pheochromocytoma/paraganglioma in adults and neuroblastoma in children; and its lead radiotherapeutic product candidate, Onalta, which is in European pivotal Phase III clinical studies for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors in patients whose symptoms are not controlled by conventional therapy. Molecular Insight Pharmaceuticals also develops Trofex, a molecular imaging radiopharmaceutical product candidate in Phase I trials for the diagnosis and detection of metastatic prostate cancer; and Solazed, a targeted radiotherapeutic under Phase I initialization, for the treatment of malignant metastatic melanoma. In addition, it is developing a non-oncology product, Zemiva, a molecular cardiovascular imaging radiopharmaceutical product candidate, which completed the Phase II trials for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart muscle. Molecular Insight Pharmaceuticals sub-licensed Onalta to BioMedica Life Sciences S.A. for development in certain countries in Europe, the Middle East, north Africa, Russia, and Turkey under a strategic collaboration agreement. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003. Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. There is a failure to deliver in shares of MIPI.

Medclean Technologies, Inc. (OTCBB: MCLN) designs, sells, installs, and services on site turnkey systems to treat regulated medical waste. It provides MedClean series systems as solutions to incineration and off site hauling of untreated waste, and other alternative treatment technologies and methodologies. The companyas MedClean system employs various equipment and machinery, including an autoclave vessel to sterilize the medical waste; the MedClean Shredder to convert sterilized waste material into non-recognizable confetti-like material qualifying the end product as safe municipal solid waste; AutoTouch control station with software and hardware components that integrate and bundle operating and data recording functions into a system for conversion and disposal of medical waste; a material transporter to mechanically transport the processed waste from shredder to the municipal solid waste compacting dumpster; and a QuietCart transport cart system to facilitate a single source containerization of the infectious waste from generation, sterilization, processing, and return for refill. It markets its MedClean systems directly to waste generators, such as hospitals, nursing homes, clinics, medical groups, health departments, laboratories, physicians, dentists, and veterinarians in private practice. The company was formerly known as Aduromed Industries, Inc. and changed its name to MedClean Technologies, Inc. in January 2009. Medclean Technologies, Inc. is based in Bethel, Connecticut. There is a failure to deliver in shares of MCLN.